Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Reduction in U.S. direct spending on originator biologics as of 2018

Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)

by Matej Mikulic, last edited Jun 13, 2018
Reduction in U.S. direct spending on originator biologics as of 2018 This statistic depicts the projected savings in spending on originator biologics in the U.S. as of 2018. The projections are provided by different agencies for several time ranges. According to the projection by ESI (Express Scripts, Inc.), some 250 billion U.S. dollars will be saved due to the use of biosimilars in the United States between 2014 and 2024.
Show more

Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Generics and biosimilars
Generics and biosimilars

All Information
in one Presentation

Generics and biosimilars

Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Generics and biosimilars"
  • Global overview
  • Top companies
  • U.S. market
  • Patent expiration
  • Savings
  • Biosimilars
The most important statistics
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.